iBio Inc (IBIO)

[guay]

... it's normally a very lengthy period of time to develop a vaccine, and it's critically important, right? Because when it's different than therapeutics, this is a vaccine that you're putting into healthy people. So, of course, we're all hopeful that, all of these vaccines will be successful in human clinical trials. However, there is some benefit, of course, to really focusing naturally on safety, since you're gonna be dosing healthy people, and also get the efficacy as well, and that's why we're taking this extra time to compare the adjuvants and antigen pairings so that we can be more confident when we go into our human clinical trials that the vaccine that we have has the right safety profile and one that can be applicable to our most vulnerable populations, so meaning, especially, the elderly. So, certainly we've got to be able to move fast. And then, once you've got hopefully an optimized, in our case, vaccine candidate to take forward, you then have to be very ready to go ahead and scale up and make sure that the manufacturing and what you're testing now in these early days in the research phase, is gonna be representative of what you're making and putting into people for human clinical trials when you’re at scale ...

from the "Coronavirus Report: The Hill's Steve Clemons interviews Thomas Isett"